Your browser doesn't support javascript.
loading
Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus.
Banerjee, Avik; Huang, Jiachen; Rush, Scott A; Murray, Jackelyn; Gingerich, Aaron D; Royer, Fredejah; Hsieh, Ching-Lin; Tripp, Ralph A; McLellan, Jason S; Mousa, Jarrod J.
Afiliação
  • Banerjee A; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
  • Huang J; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
  • Rush SA; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
  • Murray J; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.
  • Gingerich AD; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
  • Royer F; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
  • Hsieh CL; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
  • Tripp RA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.
  • McLellan JS; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
  • Mousa JJ; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.
Proc Natl Acad Sci U S A ; 119(25): e2203326119, 2022 06 21.
Article em En | MEDLINE | ID: mdl-35696580
ABSTRACT
Human metapneumovirus (hMPV) is a leading cause of morbidity and hospitalization among children worldwide, however, no vaccines or therapeutics are currently available for hMPV disease prevention and treatment. The hMPV fusion (F) protein is the sole target of neutralizing antibodies. To map the immunodominant epitopes on the hMPV F protein, we isolated a panel of human monoclonal antibodies (mAbs), and the mAbs were assessed for binding avidity, neutralization potency, and epitope specificity. We found the majority of the mAbs target diverse epitopes on the hMPV F protein, and we discovered multiple mAb binding approaches for antigenic site III. The most potent mAb, MPV467, which had picomolar potency, was examined in prophylactic and therapeutic mouse challenge studies, and MPV467 limited virus replication in mouse lungs when administered 24 h before or 72 h after viral infection. We determined the structure of MPV467 in complex with the hMPV F protein using cryo-electron microscopy to a resolution of 3.3 Å, which revealed a complex novel prefusion-specific epitope overlapping antigenic sites II and V on a single protomer. Overall, our data reveal insights into the immunodominant antigenic epitopes on the hMPV F protein, identify a mAb therapy for hMPV F disease prevention and treatment, and provide the discovery of a prefusion-specific epitope on the hMPV F protein.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 4_TD Problema de saúde: 4_measles Assunto principal: Proteínas Virais de Fusão / Infecções por Paramyxoviridae / Metapneumovirus / Anticorpos Neutralizantes / Anticorpos Monoclonais / Anticorpos Antivirais / Antígenos Virais Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 4_TD Problema de saúde: 4_measles Assunto principal: Proteínas Virais de Fusão / Infecções por Paramyxoviridae / Metapneumovirus / Anticorpos Neutralizantes / Anticorpos Monoclonais / Anticorpos Antivirais / Antígenos Virais Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2022 Tipo de documento: Article
...